Back to All Combinations

Third-Line Refractory

Prognosis
100.00% Prevalence Level 1 Treatment Line
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
Any
Treatment Implications

STANDARD (SUNLIGHT): TAS-102 + Bevacizumab (OS 10.8mo vs 7.5mo, new standard 2023). ALTERNATIVE: Fruquintinib (FRESCO-2, OS 7.4mo). Regorafenib (CORRECT, OS 6.4mo). Consider clinical trials. Re-test for actionable mutations.

Recommended Treatments
TAS-102 + Bevacizumab
Fruquintinib
Regorafenib
Clinical trials
Treatments to Avoid

No specific contraindications noted

Study References

SUNLIGHT (PMID: 37133585), FRESCO-2 (PMID: 37331369), CORRECT

Key Statistics
100.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Updated 2023: SUNLIGHT trial established TAS-102 + Bevacizumab as preferred third-line option. Superior to TAS-102 monotherapy (HR 0.61). Fruquintinib approved as additional option (FRESCO-2). Always check for targetable alterations before palliative therapy.
Information

Category: Treatment Line

Evidence Level: Level 1

Last Updated: Dec 21, 2025

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.